Media

2018

Celsee, Inc., an innovator of platforms for comprehensive single-cell identification, analysis and retrieval, announced today that they have entered a co-commercialization agreement with IncellDx, Inc., a single-cell diagnostic company offering a pioneering technology platform that enables simultaneous cell classification and single-cell analysis of proteomic and genomic biomarkers.

Read more

2017

Celsee continues to expand its intellectual property in single-cell analysis Celsee Diagnostics, an innovator in microfluidic rare-cell isolation, characterization and retrieval platforms announced today the receipt of three additional US patents for their single cell capture and analysis technologies, adding to the company’s expanding IP library. U.S. Patent No. 9610581 B2, “System and Method for […]

Read more

Innovative platform streamlines rare single-cell enrichment, characterization and retrieval Celsee Diagnostics, an innovator of cutting-edge microfluidic products for rare cell capture, characterization and retrieval, announced today that they are demonstrating their latest innovation, Celsee PREP SingleCell at the AACR Annual Meeting 2017. Single-cell analysis is used in a vast array of life science disciplines and […]

Read more

Celsee Diagnostics, an innovator of cutting-edge rare and single cell detection products, announced the appointment of John L. “Kip” Miller to its Board of Directors. Mr. Miller is an accomplished executive and entrepreneur with a proven track record of developing and growing global life science businesses, most notably at Life Technologies (now ThermoFisher Scientific) and […]

Read more

Collaborative studies will focus on the use of circulating tumor cells (CTCs) as a biospecimen for PD-L1 quantification and as a tool for tailoring therapy in metastatic lung cancer. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy and rare-cell detection products, and IncellDx, a single-cell diagnostic company offering transformative diagnostic and prognostic clinical patient information based […]

Read more

International standard registration will facilitate access to new markets Celsee Diagnostics, an innovator of cutting-edge rare cell isolation and characterization products for both clinical and research applications announced today its successful ISO13485:2003 registration ISO 13485, Medical devices – Quality management systems – Requirements for regulatory purposes, is an internationally agreed standard that sets out the requirements […]

Read more

Zomedica Pharmaceuticals Corp, (TSX-V:ZOM), a veterinary pharmaceutical and health care solutions company, today announced it has entered into a research collaboration agreement with Celsee Diagnostics, Inc., an innovator of human health products in the emerging field of liquid biopsy. The research project defined in the agreement aims to test the feasibility of Celsee’s liquid biopsy […]

Read more

2016

Microfluidic system allows for rare single-cell enrichment, analysis and retrieval. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today the receipt of it first patent in China for the company’s single-cell capture system. The patent, “Cell Capture System and Method of Use”, applies to the company’s fundamental microfluidic technology for single-cell capture, analysis and […]

Read more

Microfluidic system allows for rare single-cell enrichment, analysis and retrieval Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products announced today the receipt of another patent for the company’s single-cell capture system. The patent, “Cell Capture System and Method of Use”, applies to the company’s fundamental microfluidic technology for single-cell capture, analysis and retrieval, and was […]

Read more

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech and medical device industries, has named Celsee Diagnostics as the Medical Device Company of the Year Trailblazer silver winner. “It was an honor to receive this award. Improved enumeration and molecular […]

Read more

“System for Imaging Captured Cells” was assigned U.S. Patent No. 9404864 Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products announced today the receipt of another patent. The patent, “System for Imaging Captured Cells”, applies to the Celsee ANALYZER imaging platform, and was assigned U.S. Patent No. 9404864 by the United States Patent and Trademark Office […]

Read more

Collaborative studies will determine the feasibility of using circulating tumor cells (CTCs) as a biospecimen for mutation analysis. Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, and GENEWIZ, a global leader in R&D genomics services, announced today that they have entered into a collaboration to determine the feasibility of using circulating tumor cells (CTCs) as […]

Read more

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been selected as a 2016 Red Herring Top 100 North America winner. Red Herring Top 100 America enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1,200 privately financed companies each year in the US and Canada. […]

Read more

Biotheranostics, a leader in molecular diagnostics for cancer, announced results from a study developing a functional workflow for gene expression profiling using blood samples, providing insights into the potential for circulating tumor cell-based cancer classification that may help reduce dependency on tissue specimens. The study was presented at the American Association for Cancer Research (AACR) […]

Read more

Celsee Diagnostics, an innovator of cutting-edge liquid-biopsy products, announced today that the company has been recognized as one of the 2016 “Michigan 50 Companies to Watch,” an awards program presented by Michigan Celebrates Small Business. Celsee Diagnostics will be honored at an awards ceremony during the twelfth annual Michigan Celebrates Small Business gala event, May […]

Read more

Celsee Diagnostics, an innovator of cutting-edge products of liquid biopsy, announces the publication of “Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples” in PLOS ONE. The peer-reviewed publication, developed in collaboration with The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, […]

Read more

Abstract. Current analysis of circulating tumor cells (CTCs) is hindered by sub-optimal sensitivity and specificity of devices or assays as well as lack of capability of characterization of CTCs with clinical biomarkers. Here, we validate a novel technology to enrich and characterize CTCs from blood samples of patients with metastatic breast, prostate and colorectal cancers […]

Read more
Sign up for our newsletter and stay up to date.